Intellect Neurosciences, Inc. Issues Letter to Shareholders
March 19, 2015 07:30 ET
|
Intellect Neurosciences, Inc.
NEW YORK, March 19, 2015 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCPNK:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and...
Intellect Neurosciences, Inc. Issues Letter to Shareholders
September 24, 2014 08:00 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Sept. 24, 2014 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCPNK:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents...
Intellect Neurosciences, Inc. Issues Letter to Shareholders
August 13, 2014 08:00 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Aug. 13, 2014 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCPK:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Intellect Neurosciences, Inc. Issues Letter to Shareholders
July 31, 2014 08:00 ET
|
Intellect Neurosciences, Inc.
NEW YORK, July 31, 2014 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCPNK:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents...
![Intellect Neurosciences, Inc. Logo](/news-release/logo/227396/0/227396.jpg?lastModified=12%2F10%2F2016%2005%3A44%3A24&size=2)
Intellect Neurosciences Obtains Patent Allowance From the United States Patent and Trademark Office in Relation to Its TOC-1 Monoclonal Antibody Selective for Pre-Fibrillar Tau Aggregates
November 14, 2013 14:15 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Nov. 14, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and...
![Intellect Neurosciences, Inc. Logo](/news-release/logo/227396/0/227396.jpg?lastModified=12%2F10%2F2016%2005%3A44%3A24&size=2)
Intellect Neurosciences Retains Chain Pharmaceuticals LLC
July 30, 2013 11:30 ET
|
Intellect Neurosciences, Inc.
NEW YORK, July 30, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) announced today it has retained Chain Pharmaceuticals LLC as a consultant to assist the company in managing its...
![Intellect Neurosciences, Inc. Logo](/news-release/logo/227396/0/227396.jpg?lastModified=12%2F10%2F2016%2005%3A44%3A24&size=2)
Intellect Neurosciences, Inc. Issues Letter to Shareholders
June 20, 2013 09:25 ET
|
Intellect Neurosciences, Inc.
NEW YORK, June 20, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of treatments for the prevention and...
![Intellect Neurosciences, Inc. Logo](/news-release/logo/227396/0/227396.jpg?lastModified=12%2F10%2F2016%2005%3A44%3A24&size=2)
Intellect Neurosciences Engages Evli Corporate Finance to Explore Strategic Alternatives to Maximize Shareholder Value
June 18, 2013 11:31 ET
|
Intellect Neurosciences, Inc.
NEW YORK, June 18, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of treatments for the prevention and...
![Intellect Neurosciences, Inc. Logo](/news-release/logo/227396/0/227396.jpg?lastModified=12%2F10%2F2016%2005%3A44%3A24&size=2)
Intellect Neurosciences Issues Letter to Shareholders
March 29, 2013 09:35 ET
|
Intellect Neurosciences, Inc.
NEW YORK, March 29, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of treatments for the prevention and...
![Intellect Neurosciences, Inc. Logo](/news-release/logo/227396/0/227396.jpg?lastModified=12%2F10%2F2016%2005%3A44%3A24&size=2)
Intellect Neurosciences to Present at Bio-Europe Spring Conference in Barcelona
February 28, 2013 09:35 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Feb. 28, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, will present at the Bio-Europe Spring Conference March 11-13,...